不同免疫增强剂对肿瘤患者免疫功能的影响

目的： 了解不同免疫增强剂对肿瘤患者免疫功能的影响，并为其合理使用提供参考。方法： 对山西省肿瘤医院210例患者进行回顾性统计分析，根据其用药进行分组，各30例，均进行化疗治疗。A组为化疗同时给予免疫增强剂，给药方法为胸腺肽α1 3.2 mg·d^-1，胸腺五肽20 mg·d^-1，脾多肽8 mL·d^-1，甘露聚糖肽10 mg·d^-1，薄芝糖肽4 mL·d^-1，胎盘多肽8 mL·d^-1，B组单纯化疗，比较患者治疗前后的免疫功能指标。结果： A组和B组治疗前后的免疫指标，差异均无统计学意义（P>0.05）；胎盘多肽联合化疗治疗前CD3⁺CD8⁺低于治疗后，CD3^-CD19⁺高于治疗后，差异有统计学意义（P<0.05）；各用药组间及其与B组免疫功能指标相比较，差异无统计学意义（P>0.05）。结论： 患者化疗同时使用免疫增强剂未起到预期作用，其在临床应用上存在不合理现象，医疗机构应该提高免疫增强剂的规范使用，以指导临床合理用药。

Effects of different immune enhancing agents on immune function in patients with cancer

OBJECTIVE To learn effects of immune enhancer on immune function of cancer patients and provide a reference for the rational use of immune enhancers.METHODS A total of 210 cancer patients from Shanxi Provincial Cancer Hospital were analyzed retrospectively and randomly divided into different groups for whether patients used immune enhancers. Based on chemotherapy drugs, each patients in group A received thymosin α1 3.2 mg·d^-1, thymopentin 20 mg·d^-1, spleen polypeptides 8 mL·d^-1, mannatide 10 mg·d^-1, Baozhi glycopeptide 4 mL·d^-1, placenta polypeptide 8 mL·d^-1. Patients in group B only received chemotherapy drugs.RESULTS Six treatment groups (group A) and group B showed no stastical significance in immune indicators before and after treatment (P>0.05). Placental peptide subgroup showed decreased CD3⁺CD8⁺ and increased CD3^-CD19⁺ after treatment (P<0.05). Between group A and B, index of immune function was not significantly different (P>0.05).CONCLUSION Immune enhancers do not function as expected during chemotherapy. Medical institutions should enhance rational use of immune enhancers to guide clinical rational drug use.